Search Results

• A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/​or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  AAML1831 - A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations

• Project:EveryChild - A Registry, Eligibility Screening, Biology and Outcome Study

  Project: EveryChild a Registry, Eligibility Screening, Biology and Outcome Study

• Wingspan Stent System and Gateway PTA Balloon Catheter, HUD

  Wingspan Stent System and Gateway PTA Balloon Catheter, HUD

• A randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to placebo in adult participants with nonrelapsing secondary progressive multiple sclerosis

  A randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to placebo in adult participants with nonrelapsing secondary progressive multiple sclerosis

• The SPYRAL AFFIRM Global Clinical Study of Renal Denervation with the Symplicity Spyral Renal Denervation System in Subjects with Uncontrolled Hypertension (SPYRAL AFFIRM)

  SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

• Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

  Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

• AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion

  AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion

• Randomized, double-blind study comparing frexalimab (SAR441344) to teriflunomide in adult with relapsing multiple sclerosis

  Master protocol of two independent, randomized, double-blind Phase 3 studies comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis

• Vivistim Registry for Paired VNS Therapy (GRASP)

  Vivistim Registry for Paired VNS Therapy (GRASP)/(Bayfront)

• A randomized, open label, multi-center, active-comparator study to assess the efficacy, safety and tolerability of ofatumumab 20mg in relapsing-remitting multiple sclerosis (SOSTOS)

  A randomized, open label, multi-center, active-comparator study to assess the efficacy, safety and tolerability of ofatumumab 20mg sc monthly versus continued current therapy in relapsing-remitting multiple sclerosis after elevation of serum neurofilament light levels (SOSTOS)